ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders
results for each matter submitted to a vote at the 2017 annual
meeting are provided below.
|
a)
|
The five nominees for director were elected to serve
three-year terms ending in 2020, as follows: |
|
Nominee
|
For
|
Against
|
Abstain
|
Broker Nonvote
|
|
Michael L. Eskew
|
671,220,924
|
164,302,114
|
1,501,285
|
111,757,621
|
|
William G. Kaelin, Jr., M.D.
|
826,063,372
|
9,782,174
|
1,178,777
|
111,757,621
|
|
John C. Lechleiter, Ph.D.*
|
823,431,942
|
10,656,961
|
2,935,420
|
111,757,621
|
|
David A. Ricks
|
824,557,265
|
9,440,436
|
3,026,622
|
111,757,621
|
|
Marschall S. Runge, M.D., Ph.D.
|
826,061,582
|
9,798,818
|
1,163,923
|
111,757,621
|
2017.
|
b)
|
By the following vote, the shareholders approved an
advisory vote on compensation paid to named executive officers: |
|
For:
|
815,541,899
|
|
Against:
|
19,340,780
|
|
Abstain:
|
2,141,644
|
|
Broker Nonvote:
|
111,757,621
|
|
c)
|
By the following vote, the shareholders voted, on an
advisory basis, to hold future advisory votes on executive compensation on an annual basis: |
|
Annually
|
767,754,104
|
|
Every 2 years:
|
3,060,960
|
|
Every 3 years:
|
63,823,418
|
|
Abstain:
|
2,385,841
|
|
Broker Nonvote:
|
111,757,621
|
|
d)
|
The appointment of Ernst Young as our principal
independent auditor was ratified by the following shareholder vote: |
|
For:
|
924,079,999
|
|
Against:
|
22,685,475
|
|
Abstain:
|
2,016,470
|
|
e)
|
By the following vote, the shareholders approved the
Lilly Directors’ Deferral Plan: |
|
For:
|
826,128,999
|
|
Against:
|
8,314,528
|
|
Abstain:
|
2,580,796
|
|
Broker Nonvote:
|
111,757,621
|
|
f)
|
By the following vote, a shareholder proposal seeking a
report regarding direct and indirect political contributions was not approved: |
|
For:
|
204,118,510
|
|
Against:
|
618,529,705
|
|
Abstain:
|
14,376,108
|
|
Broker Nonvote:
|
111,757,621
|
common stock were issued and outstanding.
About ELI LILLY AND COMPANY (NYSE:LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products. ELI LILLY AND COMPANY (NYSE:LLY) Recent Trading Information
ELI LILLY AND COMPANY (NYSE:LLY) closed its last trading session down -0.34 at 81.39 with 3,626,452 shares trading hands.
